Biomedicines announced another pharma partnership Tuesday, agreeing to work on several protein therapies with the Swiss ...

Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners ...

Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop ...

Generate Biomedicines has signed a deal worth up to $1.65 billion with Novartis (NYSE: NVS) to discover and develop protein medicines across multiple disease areas.

Fusion Micro Finance Ltd, Nava Ltd, SBFC Finance Ltd and Concord Biotech Ltd are among the other losers in the BSE's 'A' group today, 24 September 2024.

Vyloy (zolbetuximab) has been given the go-ahead for use in combination with chemotherapy for the first-line treatment of ...

First quarter GAAP diluted earnings per share of $0.50 compared to a loss per share of $0.02 in Q1 FY2024 ...

New York and Bilbao, Spain, 24 September. - American equity research firm Litchfield Hills Research has just released its newest analysis of Virtualware (ENXTPA: MLVIR), in which it raises its Buy rec ...

Scott Rapoport earned his PhD in marine biology from Scripps Institution of Oceanography at UC San Diego in 2003. Drawn to ...

Inc42 and Oracle organised the first of a two-part round table titled Boardroom: Powering Data With AI to help develop ...

Landmark is a groundbreaking three-year research programme that aims to understand Parkinson’s in unprecedented detail. The ...

Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) (“Scryb” or the “Company”), announces that, further to its press release of August 6, 2024, it has extended its non-brokered private placement ...